Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated with Targeted Drugs Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Bevacizumab
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

abstract

  • Bevacizumab monotherapy resulted in prolonged disease control and few discontinuations because of adverse events in patients whose disease had progressed during treatment with other targeted therapies, including patients who were heavily pretreated.

publication date

  • February 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4965701

Digital Object Identifier (DOI)

  • 10.1016/j.clgc.2015.07.010

PubMed ID

  • 26404107

Additional Document Info

start page

  • 56

end page

  • 62

volume

  • 14

number

  • 1